KR101030416B1 - 류마티스성 관절염의 치료 - Google Patents

류마티스성 관절염의 치료 Download PDF

Info

Publication number
KR101030416B1
KR101030416B1 KR1020047011580A KR20047011580A KR101030416B1 KR 101030416 B1 KR101030416 B1 KR 101030416B1 KR 1020047011580 A KR1020047011580 A KR 1020047011580A KR 20047011580 A KR20047011580 A KR 20047011580A KR 101030416 B1 KR101030416 B1 KR 101030416B1
Authority
KR
South Korea
Prior art keywords
salt
rheumatoid arthritis
treatment
patient
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047011580A
Other languages
English (en)
Korean (ko)
Other versions
KR20040086301A (ko
Inventor
헤이키 조엔수
Original Assignee
힉스-인스티튜티 오이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 힉스-인스티튜티 오이 filed Critical 힉스-인스티튜티 오이
Publication of KR20040086301A publication Critical patent/KR20040086301A/ko
Application granted granted Critical
Publication of KR101030416B1 publication Critical patent/KR101030416B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Liquid Crystal Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020047011580A 2002-01-28 2003-01-27 류마티스성 관절염의 치료 Expired - Fee Related KR101030416B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0201882.8A GB0201882D0 (en) 2002-01-28 2002-01-28 Organic compounds
GB0201882.8 2002-01-28
PCT/EP2003/000802 WO2003063844A2 (en) 2002-01-28 2003-01-27 Treatment of rheumatoid arthritis using imatinie

Publications (2)

Publication Number Publication Date
KR20040086301A KR20040086301A (ko) 2004-10-08
KR101030416B1 true KR101030416B1 (ko) 2011-04-20

Family

ID=9929858

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047011580A Expired - Fee Related KR101030416B1 (ko) 2002-01-28 2003-01-27 류마티스성 관절염의 치료

Country Status (22)

Country Link
US (2) US20060264443A1 (enExample)
EP (1) EP1471916B1 (enExample)
JP (1) JP4398731B2 (enExample)
KR (1) KR101030416B1 (enExample)
CN (1) CN1646130A (enExample)
AT (1) ATE399555T1 (enExample)
BR (1) BR0307286A (enExample)
CA (1) CA2473158C (enExample)
DE (1) DE60321888D1 (enExample)
DK (1) DK1471916T3 (enExample)
ES (1) ES2309299T3 (enExample)
GB (1) GB0201882D0 (enExample)
IL (1) IL162983A (enExample)
MX (1) MXPA04007309A (enExample)
NO (1) NO328255B1 (enExample)
NZ (1) NZ534137A (enExample)
PL (1) PL212137B1 (enExample)
PT (1) PT1471916E (enExample)
RU (1) RU2322238C2 (enExample)
SI (1) SI1471916T1 (enExample)
WO (1) WO2003063844A2 (enExample)
ZA (1) ZA200405323B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080061A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US20050130986A1 (en) * 2003-11-21 2005-06-16 Eklund Kari K. Treatment of spondylarthropathies
CA2579353C (en) * 2004-09-08 2013-05-14 Immunaid Pty Ltd Therapeutic strategy for treating autoimmune and degenerative diseases
JP2010500283A (ja) * 2006-05-31 2010-01-07 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
CN102512421B (zh) * 2011-10-28 2013-11-06 中国科学院广州生物医药与健康研究院 哌嗪酰胺类化合物在制药中的应用
KR101386697B1 (ko) 2012-06-18 2014-04-18 아주대학교산학협력단 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
RU2580656C1 (ru) * 2014-11-20 2016-04-10 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма гидроксихлорохина немедленного высвобождения и способ ее получения
WO2020078454A1 (en) * 2018-10-18 2020-04-23 Sinomab Bioscience Limited Method of modulating autoimmunity by disrupting cis‐ligand binding of siglec type antigens
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2000076495A1 (en) * 1999-06-16 2000-12-21 Smithkline Beecham Corporation Il-8 receptor antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316884A (en) * 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5792476A (en) * 1996-12-19 1998-08-11 Abigo Medical Ab Sustained release glucocorticoid pharmaceutical composition
TW550258B (en) * 1999-05-31 2003-09-01 Hoffmann La Roche 4-phenyl-pyrimidine derivatives
GB0108606D0 (en) * 2001-04-05 2001-05-23 Novartis Ag Organic compounds
EP1414500A4 (en) * 2001-04-16 2005-01-12 Uab Research Foundation Akt and regulation of ra synovial fibroblast apoptosis
RU2318517C2 (ru) * 2001-05-16 2008-03-10 Новартис Аг Комбинация, включающая n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин и химиотерапевтический агент
US7741335B2 (en) * 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003854A1 (en) 1997-07-18 1999-01-28 Novartis Ag Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
WO2000076495A1 (en) * 1999-06-16 2000-12-21 Smithkline Beecham Corporation Il-8 receptor antagonists

Also Published As

Publication number Publication date
RU2322238C2 (ru) 2008-04-20
EP1471916A2 (en) 2004-11-03
EP1471916B1 (en) 2008-07-02
RU2004126447A (ru) 2005-07-10
HK1072192A1 (en) 2005-08-19
PL212137B1 (pl) 2012-08-31
ZA200405323B (en) 2005-08-31
PT1471916E (pt) 2008-10-03
ES2309299T3 (es) 2008-12-16
KR20040086301A (ko) 2004-10-08
NO328255B1 (no) 2010-01-18
PL370264A1 (en) 2005-05-16
CA2473158C (en) 2013-06-11
DK1471916T3 (da) 2008-10-20
WO2003063844A3 (en) 2004-04-01
JP4398731B2 (ja) 2010-01-13
BR0307286A (pt) 2004-12-28
DE60321888D1 (enExample) 2008-08-14
US20060264443A1 (en) 2006-11-23
IL162983A (en) 2010-06-16
GB0201882D0 (en) 2002-03-13
CN1646130A (zh) 2005-07-27
ATE399555T1 (de) 2008-07-15
NO20043585L (no) 2004-10-21
MXPA04007309A (es) 2005-09-12
NZ534137A (en) 2007-03-30
WO2003063844A2 (en) 2003-08-07
SI1471916T1 (sl) 2008-12-31
US20090131382A1 (en) 2009-05-21
JP2005526022A (ja) 2005-09-02
CA2473158A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
Emery et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Genovese et al. LY2439821, a humanized anti–interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study
US20090131382A1 (en) Treatment of rheumatoid arthritis using imatinib
US8784812B2 (en) Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
JP2013166765A5 (enExample)
JP2022531906A (ja) 関節炎性疾患の組み合わせ療法
US20240101690A1 (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODY
BR112021008688A2 (pt) tratamento para arterite de célula gigante
JP2005526022A5 (ja) 関節リウマチの処置
AU2007201056B2 (en) Treatment of rheumatoid arthritis using imatinib
KR20220104789A (ko) 류마티스 관절염의 치료를 위한 btk 억제제 및 아바타셉트의 조합물
CA3162956A1 (en) Use of masitinib for the treatment of eosinophilic asthma
AU2003206783A1 (en) Treatment of rheumatoid arthritis using imatinie
RU2828044C2 (ru) Комбинированное лечение артрита
US20050130986A1 (en) Treatment of spondylarthropathies
HK1072192B (en) Treatment of rheumatoid arthritis using imatinib
US20210121464A1 (en) Methotrexate for use as a medicament
Lorenzo et al. DI-011 Analysis of off-label use in biological therapies

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140414

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140414